Shamburg News · 8-K filed Nov 16, 2026, 9:01 AM EST

MetaVia Reports Preclinical Data Comparing DA-1726 With Retatrutide in Obese Mice

MTVA · MetaVia Inc.

  • Other event
  • Other
  • Materiality: low

On November 14, 2026, MetaVia Inc. presented preclinical head-to-head data at ObesityWeek 2026 comparing DA-1726 with retatrutide in diet-induced obese mice, and issued a press release on November 16, 2026 furnished as Exhibit 99.1. The study reported DA-1726 produced greater glucose lowering and comparable weight loss to retatrutide with less suppression of food intake, along with increased hepatic and circulating FGF21 at the higher dose. The company stated it is preparing a Phase 2 study of DA-1726 in MetALD and ALD targeted to begin in the second half of 2027.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 7.01, 8.01, accession 0001104659-26-127718.

Written from the filing by Shamburg Markets. Figures are as reported by the company.